Norditropin Daily denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Requires Prior Authorization for Norditropin

Prior authorization (PA) for daily somatropin therapy (Norditropin) is essentially universal among commercial insurers, including UnitedHealthcare. The denial you received likely reflects one of three scenarios: a PA was not obtained before dispensing; a PA request was submitted but denied for missing documentation; or a previously approved PA has expired and was not renewed. In all three cases, you have a clear path forward.

## Why This Denial Is Appealable

A prior-auth-required denial for Norditropin is procedural, not a determination that the drug is not medically appropriate. If the prescription meets UHC's clinical criteria — as documented by your prescriber — the PA should be approved once the correct process is followed and complete documentation is submitted. If a PA was properly submitted and wrongly denied, that denial is subject to full internal appeal and independent external review.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 and ACA §2719, you have the right to a full-and-fair review of any adverse benefit determination, including a PA denial.
• Concurrent PA + appeal: If a PA was denied on clinical grounds, file the internal appeal immediately — do not wait for a re-submission to resolve.
• External review: If the internal appeal is denied, request binding external review by an Independent Review Organization (IRO). The external-review window is generally four months from the denial date.
• Expedited option: If the authorization delay will disrupt ongoing therapy or poses a health risk, request expedited internal and external review at the same time.

## Concrete Appeal Steps and Timeline

1. Determine which scenario applies: no PA filed, PA filed and denied, or expired PA. Each requires a slightly different response. 2. If no PA was filed: contact UHC immediately to determine whether a retroactive PA is permitted (some plans allow this within a short window) and file it with complete documentation. 3. If PA was denied: pull the full denial reason and identify each missing criterion. 4. Have your prescriber complete UHC's standard prior-authorization form for growth hormone therapy, ensuring every criterion field is answered in full with supporting chart references. 5. File the internal appeal if the PA denial stands, including the completed form, prescriber letter, and diagnostic evidence. 6. Request external review if the appeal is denied.

## Documentation to Gather

• Completed PA form: UHC's current prior-authorization form for somatropin/Norditropin, fully completed by the prescriber.
• Diagnosis confirmation: Lab results confirming the qualifying condition (e.g., growth hormone stimulation test results, karyotype, growth-velocity records) with clear linkage to an FDA-approved indication.
• Prior treatment history: A chronological record of any prior growth hormone products tried, with dates started, doses, outcomes, and reason for discontinuation if applicable.
• Prescriber medical-necessity letter: States the diagnosis, the FDA-approved indication, the clinical evidence, and why Norditropin is necessary.
• Chart notes: Recent office visit notes confirming ongoing clinical need.

## Criteria-Mapping Structure

Obtain the prior-authorization criteria from the denial letter or UHC's published PA guidelines for growth hormone. Then map every requirement:

| PA Criterion | Documented Response | |---|---| | [Copy criterion verbatim from UHC PA guidelines] | [Lab value, chart note, or prescriber statement with date and source] |

Address every criterion — even those you believe are obviously met. A single unanswered criterion is the most common reason PA appeals fail.